The Sixth Annual Display of Biologics track at PEGS Europe has showcased technologies and visionaries in the field of biologics. Molecular evolution using the tools of phage, yeast, bacterial and other display methods have yielded a staggering array of bispecific antibodies, antibody-drug conjugates, immunotherapies and other constructs. The emergence of CRISPR for genome editing, deep sequencing, machine learning, AI and computational tools will be applied to improve design and efficacy of candidates.
IMPROVEMENTS IN PHAGE DISPLAY FOR AUTOIMMUNE AND ONCOLOGY
Using Phage Display and Computational Approach to Dissect Structural Determinants of Celiac Disease Autoantibodies
Daniele Sblattero, PhD, Professor, Dipartimento Scienze della Vita, Università degli Studi di Trieste
A New Phage Display Vector Allowing Direct Screening in IgG Format
Pierre Martineau, PhD, Deputy Director, Functional Screening and Targeting in Cancer, Institut de Recherche en Cancérologie de Montpellier, Inserm, Université de Montpellier - ICM
A Novel scFv Antibody Fragment to Misfolded Alpha Synuclein as a Potent Modulator of Neuroinflammation by in vivo Intransal Delivery
Jacob George, MD, Founder, Cognyxx
Streamlined Discovery and Production of Therapeutic Antibodies
Lauri Peil, Key Account and Technology Officer, Icosagen
KEYNOTE PRESENTATION: Antibodies with Affinity Switches
Stefan Dübel, PhD, Professor & Chair, iTUBS Innovationsgesellschaft Technishe Universität Braunschweig
GENOME EDITING FOR ANTIBODY ENGINEERING
High-Throughput Antibody Engineering in Mammalian Cells by Homology-Directed Mutagenesis
Sai Reddy, PhD, Associate Professor, Department of Biosystems Science & Engineering, Laboratory for Systems and Synthetic Immunology, ETH Zurich
NEW APPROACHES TO ANTIBODY LIBRARY GENERATION
SAMURAI (Solid-Phase Assisted Mutagenesis by Uracil Restriction for Accurate Integration) – A Method for Generation of High-Quality Antibody Libraries
Johan Rockberg, PhD, Assistant Professor, Protein Science, KTH Royal Institute of Technology
Generation of Neutralising Antibodies against Tenascin-C: Targeting Early Changes in the Synovial Microenvironment as a New Class of Immunotherapy?
Peter Slavny, PhD, Project Leader, IONTAS, Ltd.
Guy Hermans, PhD, CSO, Isogenica, Ltd.
Synthetic DNA Technologies Enable Antibody Discovery and Optimization
Aaron Sato, PhD, CSO, Biopharma, Twist Bioscience
NEXT GENERATION PLATFORMS FOR TARGET DISCOVERY
Synthetic Antibody Discovery against Native Antigens by CRISPR/Cas9-Induced CDR Variability
João Gonçalves, PharmD, PhD, Tenured Associate Professor, Faculdade de Farmácia Universidade Lisboa; Group Leader/Principal Investigator, Research Institute for Medicines /Instituto de Investigação do Medicamento (iMed.ULisboa)
Discovery of Potent Human Therapeutic Antibodies Using Phage and Yeast Display Technologies
Thomas Bouquin, PhD, Head of Biologics Research France, Centre de Recherche de Vitry/Alfortville, Sanofi
High Quality Antibodies for Therapeutic Applications
Vera Molkenthin, PhD, Chief Scientist, AbCheck
Next Generation Platforms for Antibody Discovery
Andrew R.M. Bradbury, MB BS, PhD, CSO, Specifica, Inc.
Novel Strategies for the Generation of Yeast Surface Display and Phage Display Antibody Libraries
Stefan Zielonka, PhD, Associate Director, Protein Engineering & Antibody Technologies, Discovery Technologies, Global Research and Development, Merck Healthcare KGaA
Single-Cell Technologies for Interpreting Antibody Function on a Repertoire Scale
Brandon DeKosky, PhD, Assistant Professor, Department of Chemical Engineering, Department of Pharmaceutical Chemistry, Kansas Vaccine Institute, The University of Kansas
* The program is subject to change without notice, due to unforeseen reason.